Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia

Ryosuke Arakawa, Hiroshi Ito, Akihiro Takano, Hidehiko Takahashi, Takuya Morimoto, Takeshi Sassa, Katsuya Ohta, Motoichiro Kato, Yoshiro Okubo, Tetsuya Suhara

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Rationale: Paliperidone ER is a novel antipsychotic drug in an extended-release (ER) formulation. As with all antipsychotics, careful dose setting is necessary to avoid side effects. Objectives: In this study, we measured striatal and extrastriatal dopamine D2 receptor occupancy during paliperidone ER treatment in patients with schizophrenia using positron emission tomography (PET) to compare regional occupancy and to estimate the optimal dose. Materials and methods: Thirteen male patients with schizophrenia participated in this 6-week multiple-dose study. Six of them took 3 mg of paliperidone ER per day, four took 9 mg, and three took 15 mg. Two to 6 weeks after first drug intake, two PET scans, one with [11C]raclopride and one with [11C]FLB 457, were performed in each patient on the same day. The relationship between the dose or plasma concentration of paliperidone and dopamine D2 receptor occupancy was calculated. Results: The dopamine D2 receptor occupancies in the striatum measured with [ 11C]raclopride and the temporal cortex measured with [ 11C]FLB 457 were 54.2-85.5% and 34.5-87.3%, respectively. ED 50 values of the striatum and temporal cortex were 2.38 and 2.84 mg/day, respectively. There was no significant difference in dopamine D 2 receptor occupancy between the striatum and the temporal cortex. Conclusions: The data from this study suggest that paliperidone ER at 6-9 mg provides an estimated level of dopamine D2 receptor occupancy between 70-80% and that the magnitude of dopamine D2 receptor occupancy is similar between the striatum and temporal cortex.

Original languageEnglish
Pages (from-to)229-235
Number of pages7
JournalPsychopharmacology
Volume197
Issue number2
DOIs
Publication statusPublished - 2008 Apr

Fingerprint

Corpus Striatum
Dopamine D2 Receptors
Temporal Lobe
Schizophrenia
Raclopride
Positron-Emission Tomography
Antipsychotic Agents
Dopamine
Paliperidone Palmitate
Pharmaceutical Preparations

Keywords

  • Dopamine D receptor occupancy
  • Extrastriatum
  • Paliperidone ER
  • Positron emission tomography
  • Schizophrenia
  • Striatum

ASJC Scopus subject areas

  • Pharmacology

Cite this

Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. / Arakawa, Ryosuke; Ito, Hiroshi; Takano, Akihiro; Takahashi, Hidehiko; Morimoto, Takuya; Sassa, Takeshi; Ohta, Katsuya; Kato, Motoichiro; Okubo, Yoshiro; Suhara, Tetsuya.

In: Psychopharmacology, Vol. 197, No. 2, 04.2008, p. 229-235.

Research output: Contribution to journalArticle

Arakawa, R, Ito, H, Takano, A, Takahashi, H, Morimoto, T, Sassa, T, Ohta, K, Kato, M, Okubo, Y & Suhara, T 2008, 'Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia', Psychopharmacology, vol. 197, no. 2, pp. 229-235. https://doi.org/10.1007/s00213-007-1029-z
Arakawa, Ryosuke ; Ito, Hiroshi ; Takano, Akihiro ; Takahashi, Hidehiko ; Morimoto, Takuya ; Sassa, Takeshi ; Ohta, Katsuya ; Kato, Motoichiro ; Okubo, Yoshiro ; Suhara, Tetsuya. / Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. In: Psychopharmacology. 2008 ; Vol. 197, No. 2. pp. 229-235.
@article{65e5aed1cfd24f3e9161cd9aff44a6d9,
title = "Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia",
abstract = "Rationale: Paliperidone ER is a novel antipsychotic drug in an extended-release (ER) formulation. As with all antipsychotics, careful dose setting is necessary to avoid side effects. Objectives: In this study, we measured striatal and extrastriatal dopamine D2 receptor occupancy during paliperidone ER treatment in patients with schizophrenia using positron emission tomography (PET) to compare regional occupancy and to estimate the optimal dose. Materials and methods: Thirteen male patients with schizophrenia participated in this 6-week multiple-dose study. Six of them took 3 mg of paliperidone ER per day, four took 9 mg, and three took 15 mg. Two to 6 weeks after first drug intake, two PET scans, one with [11C]raclopride and one with [11C]FLB 457, were performed in each patient on the same day. The relationship between the dose or plasma concentration of paliperidone and dopamine D2 receptor occupancy was calculated. Results: The dopamine D2 receptor occupancies in the striatum measured with [ 11C]raclopride and the temporal cortex measured with [ 11C]FLB 457 were 54.2-85.5{\%} and 34.5-87.3{\%}, respectively. ED 50 values of the striatum and temporal cortex were 2.38 and 2.84 mg/day, respectively. There was no significant difference in dopamine D 2 receptor occupancy between the striatum and the temporal cortex. Conclusions: The data from this study suggest that paliperidone ER at 6-9 mg provides an estimated level of dopamine D2 receptor occupancy between 70-80{\%} and that the magnitude of dopamine D2 receptor occupancy is similar between the striatum and temporal cortex.",
keywords = "Dopamine D receptor occupancy, Extrastriatum, Paliperidone ER, Positron emission tomography, Schizophrenia, Striatum",
author = "Ryosuke Arakawa and Hiroshi Ito and Akihiro Takano and Hidehiko Takahashi and Takuya Morimoto and Takeshi Sassa and Katsuya Ohta and Motoichiro Kato and Yoshiro Okubo and Tetsuya Suhara",
year = "2008",
month = "4",
doi = "10.1007/s00213-007-1029-z",
language = "English",
volume = "197",
pages = "229--235",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia

AU - Arakawa, Ryosuke

AU - Ito, Hiroshi

AU - Takano, Akihiro

AU - Takahashi, Hidehiko

AU - Morimoto, Takuya

AU - Sassa, Takeshi

AU - Ohta, Katsuya

AU - Kato, Motoichiro

AU - Okubo, Yoshiro

AU - Suhara, Tetsuya

PY - 2008/4

Y1 - 2008/4

N2 - Rationale: Paliperidone ER is a novel antipsychotic drug in an extended-release (ER) formulation. As with all antipsychotics, careful dose setting is necessary to avoid side effects. Objectives: In this study, we measured striatal and extrastriatal dopamine D2 receptor occupancy during paliperidone ER treatment in patients with schizophrenia using positron emission tomography (PET) to compare regional occupancy and to estimate the optimal dose. Materials and methods: Thirteen male patients with schizophrenia participated in this 6-week multiple-dose study. Six of them took 3 mg of paliperidone ER per day, four took 9 mg, and three took 15 mg. Two to 6 weeks after first drug intake, two PET scans, one with [11C]raclopride and one with [11C]FLB 457, were performed in each patient on the same day. The relationship between the dose or plasma concentration of paliperidone and dopamine D2 receptor occupancy was calculated. Results: The dopamine D2 receptor occupancies in the striatum measured with [ 11C]raclopride and the temporal cortex measured with [ 11C]FLB 457 were 54.2-85.5% and 34.5-87.3%, respectively. ED 50 values of the striatum and temporal cortex were 2.38 and 2.84 mg/day, respectively. There was no significant difference in dopamine D 2 receptor occupancy between the striatum and the temporal cortex. Conclusions: The data from this study suggest that paliperidone ER at 6-9 mg provides an estimated level of dopamine D2 receptor occupancy between 70-80% and that the magnitude of dopamine D2 receptor occupancy is similar between the striatum and temporal cortex.

AB - Rationale: Paliperidone ER is a novel antipsychotic drug in an extended-release (ER) formulation. As with all antipsychotics, careful dose setting is necessary to avoid side effects. Objectives: In this study, we measured striatal and extrastriatal dopamine D2 receptor occupancy during paliperidone ER treatment in patients with schizophrenia using positron emission tomography (PET) to compare regional occupancy and to estimate the optimal dose. Materials and methods: Thirteen male patients with schizophrenia participated in this 6-week multiple-dose study. Six of them took 3 mg of paliperidone ER per day, four took 9 mg, and three took 15 mg. Two to 6 weeks after first drug intake, two PET scans, one with [11C]raclopride and one with [11C]FLB 457, were performed in each patient on the same day. The relationship between the dose or plasma concentration of paliperidone and dopamine D2 receptor occupancy was calculated. Results: The dopamine D2 receptor occupancies in the striatum measured with [ 11C]raclopride and the temporal cortex measured with [ 11C]FLB 457 were 54.2-85.5% and 34.5-87.3%, respectively. ED 50 values of the striatum and temporal cortex were 2.38 and 2.84 mg/day, respectively. There was no significant difference in dopamine D 2 receptor occupancy between the striatum and the temporal cortex. Conclusions: The data from this study suggest that paliperidone ER at 6-9 mg provides an estimated level of dopamine D2 receptor occupancy between 70-80% and that the magnitude of dopamine D2 receptor occupancy is similar between the striatum and temporal cortex.

KW - Dopamine D receptor occupancy

KW - Extrastriatum

KW - Paliperidone ER

KW - Positron emission tomography

KW - Schizophrenia

KW - Striatum

UR - http://www.scopus.com/inward/record.url?scp=40949155240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40949155240&partnerID=8YFLogxK

U2 - 10.1007/s00213-007-1029-z

DO - 10.1007/s00213-007-1029-z

M3 - Article

C2 - 18058087

AN - SCOPUS:40949155240

VL - 197

SP - 229

EP - 235

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 2

ER -